Add to Favorites Newsroom RSS Share
Kansas City, KS USA

Our News on Newswise


A Tailored Approach to Minority Tobacco Cessation Programs

Researchers work with African American and American Indian communities to identify effective tobacco cessation strategies
24-Sep-2018 2:05 PM EDT Add to Favorites


Moving Homegrown Ideas into the Clinic

Physician-scientists at The University of Kansas Cancer center are designing and initiating their own clinical trials.
20-Sep-2018 11:05 AM EDT Add to Favorites


Researcher Investigates Eliminating Radiation for HER2-Positive Breast Cancer

Researchers at The University of Kansas Cancer Center have launched a clinical trial that eliminates radiation from the treatment protocol for an invasive type of breast cancer that accounts for one-fifth of all breast cancer patients.
29-Jun-2018 11:05 AM EDT Add to Favorites


Researchers Evaluate Methods for Quitting Tobacco

Researchers at The University of Kansas Cancer Center have received a five-year National Institutes of Health R0-1 grant to compare and evaluate the efficacy of optimized versus non-optimized tobacco cessation approaches for African American smokers.
26-Jun-2018 4:35 PM EDT Add to Favorites

New Drug Combination Shows Promise in Treating Ovarian Cancer

Researchers at The University of Kansas Cancer Center have discovered a therapy combination that may be helpful in the treatment of certain types of ovarian cancer.
7-Jun-2018 4:00 PM EDT Add to Favorites


The University of Kansas Cancer Center is joining forces with the nation’s top cancer centers to advocate for more HPV vaccinations

The University of Kansas Cancer Center is joining forces with a host of the nation’s top cancer centers to focus the spotlight on eliminating human papillomavirus (HPV)-related cancers in the United States.
7-Jun-2018 2:05 PM EDT Add to Favorites


Anti-cancer agent Ciclopirox Prodrug’s first-in-human Clinical Trial to be presented at ASCO 2018

The University of Kansas Cancer Center will present preclinical evidence supporting Ciclopirox Prodrug (CPX-POM), an anti-cancer agent currently in Phase I clinical trials, at the American Society of Clinical Oncology (ASCO) annual meeting in...
1-Jun-2018 9:05 AM EDT Add to Favorites

KU Medical Center Receives FDA Clearance to Proceed with Phase 1 Trial in Graft-versus-Host Disease Patients

The University of Kansas Medical Center announced that the U.S. Food and Drug Administration (FDA) has cleared it to begin a first-in-human clinical trial of MSCTC-0010 in patients with de novo high-risk acute or steroid-refractory acute...
16-May-2018 10:05 AM EDT Add to Favorites

see all news

Our Experts on Newswise


Triple-negative breast cancer expert Dr. Priyanka Sharma discusses latest research and clinical trial efforts.
18-Jul-2018 1:35 PM EDT


Getting Survivorship Care Planning Off the Page and Into Practice

Jennifer Klemp, PhD, MPH, director of cancer survivorship and an associate professor at The University of Kansas Cancer Center, is interviewed by Oncology Nursing News. In this interview, Klemp offers insights on some of the critical issues that...
31-Oct-2016 9:30 AM EDT


Rewriting the Book on Chemo-Resistant Cancers with a DNA Library

KU Cancer Center researcher is finding out why ovarian cancer is resistant to certain types of chemo to eventually identify a different drug target.
30-Jun-2015 5:05 PM EDT

see all experts

Our YouTube Videos


The University of Kansas Cancer Center is a world-class, community-based, NCI-designated cancer research and care partnership spanning two states and involving collaboration among researchers, physicians and cancer support professionals. Together, we are working toward a world without cancer. The University of Kansas Cancer Center is transforming cancer research and clinical care by linking our innovative approach to drug discovery, delivery and development to our nationally accredited patient care program. Our partnership includes cancer research and health care professionals associated with the University of Kansas Medical Center and The University of Kansas Hospital in Kansas City, The University of Kansas in Lawrence, the University of Kansas School of Medicine in Wichita, The Stowers Institute for Medical Research and the members of the Midwest Cancer Alliance. Our research programs include Cancer Biology, Cancer Prevention, Cancer Control and Population Health, and Drug Discovery, Delivery and Experimental Therapeutics. Shared resources include Biospecimen, Biostatistics and Informatics, Clinical Research Office and Lead Development and Optimization.

Disease-specific working groups, including both clinicians and basic research investigators, promote collaborative opportunities and the exchange of research ideas. The disease working groups define clinical research priorities respective to their disease specialty with an emphasis on Investigator Initiated Trials (IITs). The cancer center’s current disease working groups include lung, hematology/bone marrow transplant, gastrointestinal, genitor-urinary, head and neck, breast and brain.

Breaking new ground in cancer research requires state-of-the-art facilities. A 82,400-square-foot University of Kansas Clinical Research Center, which opened in January 2012, houses the Phase I clinical trials program. A recently remodeled, 170,000-square-foot Wahl/Hixon research complex, known as The Kansas Masonic Cancer Research Institute, will house 37 cancer-focused researchers. Building a world-class cancer center that is at the forefront of discovery, development and implementation is just the beginning. The legacy of The University of Kansas Cancer Center endures when discoveries made here benefit cancer patients everywhere.


Kay Hawes
Assoc. Dir of News & Media Relations
Health Care


Pauline Horton
Communications Specialist


Natalie Lutz
Executive Director, Marketing & University Relatio


Donna Peck
Assistant Communications Director


Christine Wilson
Director of Public Relations



Chat now!